Stefanos Grammatikos
Monday 1st July 2024, 16:30-17:30
Stefanos Grammatikos is heading since 2013 Biotech Sciences, the end-to-end CMC Development organization he built at UCB to support the company’s biologics and more recently AAV-based gene therapy portfolio. Major achievement of Biotech Sciences during his tenure has been the successful CMC development from candidate selection to launch of two highly innovative marketed monoclonal antibodies: Bimzelx® and Rystiggo®. Prior to UCB, Stefanos held several leadership positions in bioprocess development and biologics manufacturing at Boehringer Ingelheim Pharma in Germany. As early as 1998 he realized the importance of cell line development to biopharmaceutical manufacturing and initiated at BI a pioneering concept for clone selection including FACS and early high-throughput automation and miniaturization. In recognition of his contribution and service to the Animal Cell Technology community, he was awarded in 2015 the Medal of the European Society for Animal Cell Technology (ESACT) and is serving since 2022 as Vice-Chair of the Society.
Visit us on Social Media
#ECB2024
Please note: All information requested on the website and registration process is strictly for the use of the Congress in compliance with international privacy legislation. By completing this registration form you will agree that the Congress will use this data to keep you fully informed of the Congress in 2024. The data will then be retained by the Congress secretariat for the purposes of informing you about activities and future meetings. On the registration form, You will also have the opportunity to agree separately to allow key data (Name, Company, Email Address) to be shared with sponsors and exhibitors who are participating in the Congress in 2024. We will not pass any details to any companies not participating in the Congress in 2024.